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In this issue of Neuron, Todd et al. (2013) reveal that noncanonical repeat associated non-AUG (RAN) trans-
lation occurs on nonexpanded (CGG)30–50 and premutation (CGG)59–160 repeats, associated with the
FMR1 gene, suggesting that the polyglycine and polyalanine products might have natural and pathogenic
roles.‘‘Well, in our country,’’ said Alice,
still panting a little, ‘‘you’d generally
get to somewhere else—if you run
very fast for a long time, as we’ve
been doing.’’
‘‘A slow sort of country!’’ said the
Queen. ‘‘Now, here, you see, it
takes all the running you can do, to
keep in the same place. If you want
to get somewhere else, you must
run at least twice as fast as that!’’
—Lewis Carroll,
Through the Looking-Glass
Typically, DNA is transcribed to make
an RNA, which is translated to make a
protein. This translation almost always
requires a signal that says, ‘‘Translation
begins here.’’ This signal is an ATG motif.
Moreover, typically one RNA encodes
only one protein. In this issue of Neuron,
Todd et al. (2013) reveal that the nonca-
nonical process of repeat associated
non-AUG (RAN) translation occurs on
the CGG repeat tract present in the 50
UTR of FMR1. Expanded CGG repeats
in FMR1 have been associated with three
diseases including fragile X mental retar-
dation type A (FRAXA), fragile X-asso-
ciated premature ovarian insufficiency
(FXPOI), and fragile X-associated tremor
ataxia syndrome (FXTAS) (Oostra and
Willemsen, 2009; Lo´pez Castel et al.,
2010) (Figure 1). In unaffected individuals,
the repeat is (CGG)6–52, in premutation
individuals it is (CGG)59–200, and in
FRAXA individuals it is (CGG)230–2,000
and aberrantly methylated at CpG sites
coincident with loss of transcription and
FMRP protein. Individuals with premuta-
tion lengths show increased levels of theFMR1 transcript and the CCG-containing
FMR4 transcript from the strand comple-
mentary to FMR1 (Pearson et al., 2005;
Oostra and Willemsen, 2009; Lo´pez Cas-
tel et al., 2010) and can present with
FXTAS or FXPOI, both of which are
thought to be caused by toxic RNAs,
protein binding, and sequestration,
similar to myotonic dystrophy (Jin et al.,
2003; Lu et al., 2012). The findings
of Todd et al. (2013) now reveal a
novel pathogenic path for FMR1-related
diseases.
RAN translation was recently demon-
strated by the Ranum laboratory to be
a novel form of translation in which
there is an absence of an initiating AUG
motif and initiation begins within all
reading frames of an expanded (CAG)N
repeat (Zu et al., 2011; Pearson, 2011).
Such events occurred in tissues of
myotonic dystrophy type 1 (DM1) and
spinocerebellar ataxia type 8 (SCA8)
patients. Similar findings were recently
reported for the C9orf72 (GGGGCC)N
repeat in tissues of amyotrophic lateral
sclerosis and frontotemoral dementia
patients, yielding a series of dipeptide
repeats (Mori et al., 2013; Ash et al.,
2013). The excitement of this newly
discovered RAN translation has kept
many scientists running, much as Alice
did to keep up with the Queen in Lewis
Carroll’s Through the Looking-Glass.
Todd et al. (2013) now demonstrate
similar but not identical phenomena
at the FMR1 CGG tract, whereby
translation of the repeat occurred in
the .C GGC GGC GG. or the .CG
GCG GCG G. reading frames, yielding
peptides of polyglycine or polyalanine.
Polyarginine from the .CGG CGG
CGG. reading frame was undetectable.NeuroFunctions and Pathogenesis of CGG
RAN Translation
What is the role, if any, of RAN-translated
products in pathogenesis and can this
be distinguished from the pathogenic
contribution of the CGG RNA? Separating
the individual pathogenic contributions
of the expanded RNA from that of RAN-
translated peptides is a tough challenge,
as expression of one without the other
is limited by the codons encoding the
homopolymers polyGly, polyAla, and pol-
yArg, all of whose codons are redundant
enough to have some repetitive nature.
Identification of a factor required for
RAN translation that is not required for
RNA toxicity would ideally separate the
contributions of each. Todd et al. (2013)
show that transfection of a CGG repeat
into human cells reduced cell viability
that depended upon both repeat length
and translation levels. In Drosophila,
RAN translation of an expanded CGG
RNA caused retinal degeneration. A
polyGly-mediated effect was supported
by enhancing or suppressing protein
quality control pathways, which modu-
lated retinal degeneration in (CGG)90
GFP-expressing flies. Thus, both toxic
CGG RNA and toxic RAN proteins may
contribute to disease pathogenesis. An
interesting clue came from the analysis
of two mouse models of FXTAS with
slightly different constructs. One line,
in which premutation CGG repeats inte-
grated into the 50 UTR of the mouse
fmr1, showed more polyGly inclusions.
High levels of inclusions were present in
the CNS, whereas inclusions were less
frequent in a second knockin mouse
that had retained a TAA stop codon just
50 of the integrated CGG tract, which is
predicted to reduce RAN translation.n 78, May 8, 2013 ª2013 Elsevier Inc. 405
Figure 1. RAN Translation in CGG Repeats
RAN translation occurs in nonexpanded and expanded premutation CGG repeats associated with FXTAS, FXPOI, and the testis and sperm of FRAXA males.
Table: RAN-translatable disease-associated genes and rare fragile sites whose expanded repeats may undergo RAN translation.
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PreviewsThis stop codon was not present in
the former mouse model. Since nuclear
inclusions containing RAN-translated
products were only evident in human
FXTAS brains and not controls without
CGG expansions, Todd et al. (2013) pro-
pose that, although RAN translation
occurs in both cases, only the expanded406 Neuron 78, May 8, 2013 ª2013 Elsevier ICGG repeat leads to protein aggregation
and inclusion formation. Identifying age-
matched asymptomatic individuals posi-
tive for premutation lengths but negative
for RAN-peptide inclusions would further
support the proposal of Todd et al.
(2013) that inclusions are pathogenic to
FXTAS. Evidence for or against the patho-nc.genic contribution of RAN inclusions in
any of the repeat diseases is needed.
Interestingly, RAN translation arose
from nonexpanded lengths of r(CGG)30
repeats. This leads to two important ques-
tions. First, what roles do RAN translation
products have, if any, in the unaffected
population? Such nonpathogenic roles
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Previewsmight be the reason that CGG repeats
were evolutionarily retained, even though
they can be unstable and lead to disease.
Second, what is the clinical effect when
RAN-translation products are lost? Fragile
X syndrome has long been thought to be
due to a loss of the FMRP protein, medi-
ated by loss of FMR1 transcription, which
would also lead to loss of RAN-translation
products. A unique female hemizygous for
the FRAXA locus due to a large deletion
encompassing FMR1 of one X chromo-
some and on the other X chromosome a
microdeletion in FMR1 including all CGG
repeats plus some flanking sequences,
leaving transcription and translation start
sites intact, displayed FMRP expression
and a non-FRAXA presentation (Grønskov
et al., 1997). This individual would be
devoid of FMR1 RAN-translation prod-
ucts. Whether the other symptoms of
the patient (hearing problems and some
deficits in perceptual spatial skills) were
the result of the lossofFMR1RAN-transla-
tion products or the very large deletion on
the other X chromosome is not known. A
FRAXA individual without CGG expan-
sions but having an FMRP-inactivating
point mutation, I304N, that still produces
a (CGG)25-containingmRNAandpresum-
ably RAN-translation products, argues
that there is little phenotypic contribution
of the loss of RAN translation to the typical
FRAXA presentation (Oostra and Willem-
sen, 2009; Pearson et al., 2005). The natu-
ral functions of RAN-translation products
deserve attention (Pearson, 2011).
Mechanism(s) of CGG RAN
Translation
Using Drosophila, CGG mouse models,
human cell lines, and patient tissues,
Todd et al. (2013) observed RAN transla-
tion on both nonexpanded and disease-
associated premutation CGG lengths
in two of the three possible reading frames
(GGC,polyGly andGCG,polyAla) involving
distinct RAN-translation mechanisms for
each frame.RAN translation leading topol-
yGly requiredanupstreamAUG-likecodon
(such as GUG) and was sensitive to stop
codons. PolyAla formation arose indepen-
dent of AUG-like codons, was insensitive
to stop codons, and was repeat length
dependent. Thus, there aremultiplemech-
anisms governing CGG RAN translation.
Placement of a stop codon at 12 bp,
but not at 21 bp, upstream of the CGGblocked RAN translation of polyGly, sug-
gesting that RAN translation initiates be-
tween 21 and 12 bases 50 of the CGG
repeat (Figure 1). Interestingly, this same
region of the FMR1 transcript had previ-
ously been identified to function as an in-
ternal ribosome entry site (IRES) and a
site of ribosome pausing (Chiang et al.,
2001). Similar to the reduced translation
of FMRP from the premutation FMR1
CGG repeat compared to the nonex-
panded sizes (Pearson et al., 2005; Oostra
and Willemsen, 2009), RAN translation in
the polyGly frame may also be decreased
with longer tracts (Todd et al., 2013).
RAN translation of (CAG)N repeats
required the formation of an intrastrand
hairpin in the r(CAG)n RNA (Zu et al.,
2011), where RNA structure may impact
initiation of RAN translation (Pearson,
2011). FMR1 r(CGG)19–47 repeats were
shown to form hairpins, complex multi-
branched or G-quadruplex structures (Na-
pierala et al., 2005; Khateb et al., 2007).
Interestingly, the C9orf72 repeat, which
also undergoes RAN translation (Mori
et al., 2013; Ash et al., 2013), was recently
demonstrated to form G-quadruplexes
(Reddy et al., 2013). The precise RNA
structures and contexts (AUG-like motifs)
involved in RAN translation of each repeat
sequence, and possibly each reading
frame, needs to be elucidated.
Where Else Might CGG RAN
Translation Occur?
Presumably, CGG-mediated RAN transla-
tion and the production of toxic polypep-
tides/inclusions may form wherever an
expanded CGG repeat-containing tran-
script is produced (Figure 1). The clinical
presentation of FMR1 mutations
is modulated by CGG tract length and
aberrantCpGmethylation.FRAXApatients
exhibit nearly completemethylation of their
expandedCGG tract,whereas rare individ-
uals classified as ‘‘high-functioning’’ males
or ‘‘methylation mosaics’’ possess unme-
thylated CGG repeats expanded to dis-
ease lengths and display FMR1 transcrip-
tion and FMRP protein and are not
affected (Pearson et al., 2005). Albeit,
males with fully expanded and methylated
repeats do show some FMR1 transcript
(Pearson et al., 2005; Oostra and Willem-
sen, 2009). Furthermore, unmethylated
premutation (CGG)59–230 lengths, which
are both transcribed and translated toNeuroFMRP, exist in the testes and sperm of
males with full-mutation FRAXA, even
though all other tissues displaymethylated
disease-length alleles of (CGG)230–2,000
(Pearson et al., 2005). In all of the above in-
stances, the FMR1 and FMR4 transcripts
with fully expanded or premutant CGG
and CCG tracts may be templates for
RAN translation and their potentially toxic
products. Other fragile site genes, each
associated with expanded CGG repeats
and their CCG-containing antisense tran-
scripts, may also undergo RAN translation
(Figure 1), as might any of the disease-
associated expanded CAG/CTG repeats
(Pearson, 2011).
Does RAN translation occur in all
premutations, FXPOI tissues, high-func-
tioning methylation mosaics with fully
expanded CGG repeats, or is it limited
to FXTAS patients (Figure 1)? Both unme-
thylated full mutation and premutation
alleles show increased FMR1 transcript
levels (Pearsonetal., 2005;OostraandWil-
lemsen, 2009). Might RAN translation of
theCGGtract besensitive to repeat length,
in that premutation expansions associated
with FXTAS, but not fully expanded (CGG)
230–2,000 tracts, are susceptible to this
phenomenon? Might the very large CGG
tracts be recalcitrant to RAN translation,
as premutation lengths are recalcitrant to
FMRP translation (Pearson et al., 2005;
Oostra and Willemsen, 2009)?
That RAN translation occurs on CGG
repeats of nonexpanded and premu-
tation length transcripts broadens our
understanding of both the naturally
occurring FMR1 gene products as well
as the potential toxic entities that may
be involved in FXTAS, FXPOI, and FRAXA.
This adds FMR1 to the growing list of
disease-associated repeats that undergo
RAN translation and those that might
be (Figure 1), with some evidence of a
pathogenic role, and may be common
to the 40 repeat-associated diseases.
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In this issue of Neuron, Fo¨ldy et al. (2013) report that endocannabinoid-mediated signaling at inhibitory
synapses is dysregulated in mouse models of autism-associated Neuroligin-3 mutations. These findings
carry implications regarding the pathophysiology of autism spectrum disorders and the development of
treatment strategies.The correct wiring of the brain during
development is an extremely complex
biological process, during which a stag-
gering number of synapses with often
very diverse characteristics have to be
formed and maintained in a precise
and delicate balance. Not surprisingly,
therefore, numerous neurodevelopmental
and psychiatric diseases appear to be
disorders of aberrant synaptogenesis
and synapse function, or ‘‘synaptopa-
thies.’’ Particularly in the context of autism
spectrum disorders (ASDs), an ever-
growing number of mutations in genes
encoding synaptic proteins have been
identified in affected individuals (Murdoch
and State, 2013), and major research ef-
forts are currently focusing on strategies
to transform this knowledge base into
viable treatment strategies.
However, the corresponding chal-
lenges are substantial. For example, very
little is known about the role of ASD-related synaptic proteins in vivo, e.g., in
neuronal circuits that control autism-
relevant behavior. Second, many known
ASD-related proteins are structural pro-
teins with adhesion or scaffold functions
and therefore poor targets for pharmaco-
logical intervention with small molecule
drugs. Third, many ASD-related muta-
tions lead to a loss of the corresponding
protein so that no target for pharmaco-
logical intervention remains. Finally, each
individual ASD-related mutation is rare,
with the vast majority accounting for less
than 1% of affected individuals each. In
view of these difficulties, the focus in the
field of ASD biology has shifted toward
the identification of cellular protein-pro-
tein interactions or signaling pathways
that are common to the various ASD-
related proteins and therefore expected
to be perturbed by a wide range of
ASD-related mutations—with the hope
that such pathways may represent morepromising treatment targets than the
ASD-linked proteins discovered so far.
One of the synaptic proteins associated
with ASDs is Neuroligin-3 (NLGN3), a
member of the Neuroligin family of post-
synaptic cell adhesion molecules that
interact with presynaptic Neurexins to
control synapse development and func-
tion. Two distinct mutations in NLGN3
have been linked to ASDs, a point muta-
tion resulting in an R451C substitution in
the Neurexin-binding domain (Jamain
et al., 2003) and a deletion of the NLGN3
gene (Sanders et al., 2011). Studies
on the respective mouse models, a
Nlgn3R451C knockin (KI) and a Nlgn3
knockout (KO), showed that both muta-
tions cause ASD-related behavioral phe-
notypes (Radyushkin et al., 2009; Tabuchi
et al., 2007) but have strikingly different
effects on synapse and network function,
with the Nlgn3R451C mutation resulting
in a gain-of-function phenotype that is
